Truist cuts Amentum stock price target to $35 on valuation pressure

Truist lowered Amentum’s price target to $35 from $42 but kept a Buy rating, while RBC cut its target to $28 and Citizens reiterated Market Outperform with a $40 target. Amentum reported fiscal Q2 2026 adjusted EPS of $0.60, beating the $0.57 consensus and up from the prior $0.37 forecast, on revenue of $3.5 billion, up 3% year over year. The company also highlighted $600 million of quarterly awards in its CDI growth area, though it flagged a potential 1% revenue headwind from NASA insourcing in fiscal 2027.

Analysis

AMTM’s read-through is less about the headline valuation reset and more about the quality of its backlog mix. The market is starting to separate “good growth” from “cheap growth”: awards in higher-scrutiny CDI work can support multiple expansion only if execution stays clean, while timing noise in DS margins keeps the stock vulnerable to quarterly de-rating. The combination of a low PEG and a steep recent drawdown suggests the selloff has been driven more by sentiment compression than by a broken earnings path.

The bigger second-order issue is customer concentration risk under the hood. Even a modest NASA insourcing headwind in FY27 can matter if investors extrapolate it into a broader federal make-or-break narrative, because that would likely pressure multiples before it hits reported numbers. On the other hand, if Amentum proves it can convert large quarterly awards into sustained revenue without leverage creep, it becomes a beneficiary of the market’s preference for defense/infrastructure cash flows with visible mid-single-digit growth.

Consensus appears to be anchoring on valuation compression in government services as a sector-wide excuse to cut targets, but that may underappreciate the spread between companies with merger integration momentum and those with stagnant book-to-bill. The move looks somewhat overdone if the next one or two quarters merely confirm stable margins and continued award flow. The real downside would come from a slowdown in award conversion or any sign that the cost structure cannot absorb program timing volatility, which would likely hit the stock faster than the revenue line over the next 1-2 quarters.

Key Decisions for Investors

• Buy AMTM on weakness into the next 1-2 earnings cycles; target a re-rating toward $30-$35 if awards convert and margins hold, with downside risk to the low-$20s if CDI momentum stalls.
• Use a defined-risk call spread in AMTM, e.g. 3-6 month upside structure, to express mean reversion without paying full equity beta; favorable if the stock simply mean-reverts to peer valuation.
• Pair long AMTM / short a lower-quality government services peer with weaker growth and less visible awards; the trade should benefit from investors rewarding backlog quality rather than sector multiple compression.
• If concerned about FY27 NASA insourcing becoming a narrative overhang, consider trimming on strength above prior target cuts and re-entering after the next two quarters confirm whether the issue is isolated or structural.